Entering text into the input field will update the search result below

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2020 Results - Earnings Call Transcript

May 07, 2020 10:06 AM ETIVERIC bio, Inc. (ISEE)
SA Transcripts profile picture
SA Transcripts

IVERIC bio, Inc. (NASDAQ:ISEE) Q1 2020 Earnings Conference Call May 6, 2020 8:00 AM ET

Company Participants

Kathy Galante - Investor Relations

Glenn Sblendorio - President and Chief Executive Officer

David Guyer - Executive Chairman

Dave Carroll - Chief Financial Officer

Pravin Dugel - Chief Strategy and Business Officer

Kourous Rezaei - Chief Medical Officer

Abraham Scaria - Chief Scientific Officer

Keith Westby - Chief Operating Officer

Conference Call Participants

David Nierengarten - Wedbush Securities


Good day and welcome to the IVERIC bio First Quarter 2020 Results Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Kathy Galante. Please go ahead.

Kathy Galante

Good morning and welcome to IVERIC bio’s conference call. Representing IVERIC bio today is Mr. Glenn Sblendorio, Chief Executive Officer and President; Dr. David Guyer, Executive Chairman; Mr. Dave Carroll, Chief Financial Officer; Dr. Pravin Dugel, Chief Strategy and Business Officer; Dr. Kourous Rezaei, Chief Medical Officer; Dr. Abraham Scaria, Chief Scientific Officer; and Mr. Keith Westby, Chief Operating Officer.

We would like to remind you that today we will be making statements relating to IVERIC bio’s future expectations regarding operational, financial and research and development matters, including statements regarding the impact of the COVID-19 pandemic on our research and development programs, operations and financial position and on the practices of the retinal specialists and the conduct of clinical trials; our expectations to use OPH2003, our previously announced clinical trial of Zimura for the treatment of geographic atrophy as a Phase 3 clinical trial; our development and regulatory strategy for Zimura, including our plans and expectations for a second Phase 3 clinical trial evaluating Zimura for the treatment of geographic atrophy; our hypothesis regarding complement inhibition and the mechanism of action for the treatment of geographic atrophy; our projected use of cash and cash balances; the

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.